These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15980370)

  • 21. Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis.
    Pantel A; Petrella S; Veziris N; Brossier F; Bastian S; Jarlier V; Mayer C; Aubry A
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1990-6. PubMed ID: 22290942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009.
    Cui Z; Wang J; Lu J; Huang X; Hu Z
    BMC Infect Dis; 2011 Mar; 11():78. PubMed ID: 21443804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis.
    Pantel A; Petrella S; Veziris N; Matrat S; Bouige A; Ferrand H; Sougakoff W; Mayer C; Aubry A
    J Antimicrob Chemother; 2016 Sep; 71(9):2428-31. PubMed ID: 27234461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin.
    Nosova EY; Bukatina AA; Isaeva YD; Makarova MV; Galkina KY; Moroz AM
    J Med Microbiol; 2013 Jan; 62(Pt 1):108-113. PubMed ID: 23019190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis.
    Bernard C; Veziris N; Brossier F; Sougakoff W; Jarlier V; Robert J; Aubry A
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1519-24. PubMed ID: 25534742
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.
    Singh P; Jain A; Dixit P; Prakash S; Jaiswal I; Venkatesh V; Singh M
    J Antibiot (Tokyo); 2015 Jan; 68(1):63-6. PubMed ID: 25052485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis.
    Sirgel FA; Warren RM; Streicher EM; Victor TC; van Helden PD; Böttger EC
    J Antimicrob Chemother; 2012 May; 67(5):1088-93. PubMed ID: 22357804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.
    Niward K; Ängeby K; Chryssanthou E; Paues J; Bruchfeld J; Jureen P; Giske CG; Kahlmeter G; Schön T
    J Antimicrob Chemother; 2016 Feb; 71(2):333-8. PubMed ID: 26538509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay.
    Kambli P; Ajbani K; Sadani M; Nikam C; Shetty A; Udwadia Z; Rodwell TC; Catanzaro A; Rodrigues C
    Tuberculosis (Edinb); 2015 Mar; 95(2):137-41. PubMed ID: 25522842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
    Fillion A; Aubry A; Brossier F; Chauffour A; Jarlier V; Veziris N
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4496-500. PubMed ID: 23836169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India.
    Singhal R; Reynolds PR; Marola JL; Epperson LE; Arora J; Sarin R; Myneedu VP; Strong M; Salfinger M
    J Clin Microbiol; 2016 Sep; 54(9):2298-305. PubMed ID: 27335153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay.
    Chakravorty S; Aladegbami B; Thoms K; Lee JS; Lee EG; Rajan V; Cho EJ; Kim H; Kwak H; Kurepina N; Cho SN; Kreiswirth B; Via LE; Barry CE; Alland D
    J Clin Microbiol; 2011 Mar; 49(3):932-40. PubMed ID: 21191047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.
    Wang JY; Lee LN; Lai HC; Wang SK; Jan IS; Yu CJ; Hsueh PR; Yang PC
    J Antimicrob Chemother; 2007 May; 59(5):860-5. PubMed ID: 17412727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.
    Aldred KJ; Blower TR; Kerns RJ; Berger JM; Osheroff N
    Proc Natl Acad Sci U S A; 2016 Feb; 113(7):E839-46. PubMed ID: 26792518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco.
    Chaoui I; Oudghiri A; El Mzibri M
    J Glob Antimicrob Resist; 2018 Mar; 12():171-174. PubMed ID: 29033301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characteristics of ofloxacin mono-resistant Mycobacterium tuberculosis isolates from new and previously treated tuberculosis patients.
    Wang Z; Xie T; Mu C; Wang C; Ju H; Zhao H; Sun R
    J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28317169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates.
    Sun Z; Zhang J; Zhang X; Wang S; Zhang Y; Li C
    Int J Antimicrob Agents; 2008 Feb; 31(2):115-21. PubMed ID: 18164184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of DNA Gyrase Activity and Elucidation of the Impact of Amino Acid Substitution in GyrA on Fluoroquinolone Resistance in Mycobacterium avium.
    Thapa J; Chizimu JY; Kitamura S; Akapelwa ML; Suwanthada P; Miura N; Toyting J; Nishimura T; Hasegawa N; Nishiuchi Y; Gordon SV; Nakajima C; Suzuki Y
    Microbiol Spectr; 2023 Jun; 11(3):e0508822. PubMed ID: 37067420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. gyrA/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China.
    Long Q; Li W; Du Q; Fu Y; Liang Q; Huang H; Xie J
    Int J Antimicrob Agents; 2012 Jun; 39(6):486-9. PubMed ID: 22526012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.
    Sayadi M; Zare H; Jamedar SA; Hashemy SI; Meshkat Z; Soleimanpour S; Hoffner S; Ghazvini K
    BMC Infect Dis; 2020 Jun; 20(1):390. PubMed ID: 32487030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.